share_log

Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $59

Benzinga ·  Dec 26, 2023 10:46

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target from $61 to $59.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment